Autonomic Nervous System Drugs Practice Questions

Q: Cholinomimetic is not used for:

Bradycardia. ***Bradycardia*** - **Cholinomimetics** generally cause **bradycardia** (slowing of heart rate) due to their parasympathomimetic effects. Therefore, they are contraindicated in cases of existing bradycardia. - Using them in a patient with bradycardia would further decrease heart rate, potentially leading to adverse cardiovascular events. *Open angle glaucoma* - **Cholinomimetics** (e.g., pilocarpine) are used in open-angle glaucoma to cause **miosis** (pupil constriction) and **ciliary muscle contraction**. - This action increases the outflow of **aqueous humor** through the trabecular meshwork, thus reducing intraocular pressure. *Cobra bite* - **Neurotoxic snake venoms**, such as from a cobra, contain toxins that block acetylcholine receptors at the **neuromuscular junction**. - **Cholinomimetics** (specifically acetylcholinesterase inhibitors like neostigmine) can be used as an adjunct treatment to overcome this block by increasing the concentration of acetylcholine in the synaptic cleft. *Myasthenia gravis* - **Myasthenia gravis** is an autoimmune disease where antibodies block or destroy **nicotinic acetylcholine receptors** at the neuromuscular junction, leading to muscle weakness. - **Cholinomimetics** (specifically acetylcholinesterase inhibitors like pyridostigmine) are a cornerstone of treatment as they increase the amount of acetylcholine available to bind to the remaining functional receptors, improving muscle strength.

Q: Which of the following drugs is not used for the treatment of overactive bladder?

Duloxetine. ***Duloxetine*** - **Duloxetine** is a **serotonin-norepinephrine reuptake inhibitor (SNRI)** primarily used to treat major depressive disorder, generalized anxiety disorder, neuropathic pain, and **stress urinary incontinence (SUI)** [3]. - While it affects neurotransmitters involved in bladder control, its primary indication is SUI through increasing urethral sphincter tone, not directly treating the urgency and frequency associated with **overactive bladder (OAB)** [3]. *Darifenacin* - **Darifenacin** is a **M3 muscarinic receptor antagonist** that selectively targets receptors in the bladder, reducing detrusor muscle contractions [1]. - This action helps to alleviate symptoms of urgency, frequency, and urge incontinence characteristic of **overactive bladder (OAB)** [1]. *Oxybutynin* - **Oxybutynin** is a **non-selective muscarinic receptor antagonist** that relaxes the detrusor muscle of the bladder, decreasing bladder contractility [1], [2]. - It is a long-standing and commonly used medication for managing the symptoms of **overactive bladder (OAB)** and neurogenic bladder [2]. *Flavoxate* - **Flavoxate** is a **direct relaxant of smooth muscle** in the urinary tract, and it has mild anticholinergic, local anesthetic, and analgesic properties. - It is used to relieve symptoms like dysuria, urgency, and nocturia associated with various urinary tract conditions including **overactive bladder (OAB)** and interstitial cystitis.

Q: The H3 receptor agonist exhibits all of the following actions except:

Increase in H2 mediated gastric secretion. ***Increase in H2 mediated gastric secretion*** - H3 receptor agonists inhibit the release of **histamine** from presynaptic terminals. - Less histamine means **reduced stimulation of parietal cells** (which are H2-mediated) and a decrease, not an increase, in gastric acid secretion. - H3 agonists would therefore **reduce, not increase**, H2-mediated gastric secretion. *Inhibition of H1 receptors induced wakefulness* - H3 receptor agonists reduce the release of histamine from histaminergic neurons, leading to **decreased H1 receptor activation** in the brain. - This diminished H1 activation contributes to a **reduction in wakefulness** and promotion of sleep. - This is a **true action** of H3 agonists. *Inhibition of H1 mediated bronchoconstriction* - By decreasing histamine release, H3 receptor agonists lower the amount of histamine available to bind to H1 receptors on **bronchial smooth muscle**. - This results in a **reduction in H1-mediated bronchoconstriction**. - This is a **true action** of H3 agonists. *Negative chronotropic effect on atria* - H3 receptors are present in the heart, and their activation can lead to a **reduction in heart rate** (negative chronotropic effect). - This effect is mediated through the **inhibition of histamine release locally** or directly on cardiac cells. - This is a **true action** of H3 agonists.

Q: Which of the following is not a carbamate?

Edrophonium. ***Edrophonium*** - **Edrophonium** is a **short-acting acetylcholinesterase inhibitor** that is not a carbamate. - Its action is very rapid in onset and brief in duration, unlike carbamates which have a longer duration of action due to a more stable bond with acetylcholinesterase. *Physostigmine* - **Physostigmine** is a **tertiary amine carbamate** that can cross the blood-brain barrier. - It works by reversibly inhibiting acetylcholinesterase, leading to increased acetylcholine levels, and has a duration of action of 2-4 hours. *Neostigmine* - **Neostigmine** is a **quaternary ammonium carbamate** that does not cross the blood-brain barrier effectively. - It is used to treat myasthenia gravis and reverse the effects of non-depolarizing neuromuscular blockers, with a duration of action of 2-4 hours. *Pyridostigmine* - **Pyridostigmine** is also a **quaternary ammonium carbamate** and is commonly used for the long-term treatment of myasthenia gravis. - Like neostigmine, it does not cross the blood-brain barrier and has a longer duration of action (3-6 hours) compared to physostigmine.

Q: Sympathomimetic drugs are useful in the therapy of all of the following conditions except:

Hypertension. ***Hypertension*** - Sympathomimetic drugs **mimic the effects of the sympathetic nervous system**, leading to **increased heart rate, contractility, and vasoconstriction**, which would worsen hypertension. - Their primary action is to activate **adrenergic receptors**, thereby elevating blood pressure rather than lowering it. - Sympathomimetics are **contraindicated in hypertensive patients** as they would exacerbate the elevated blood pressure. *Hypotension* - Sympathomimetic drugs are highly effective in treating hypotension, particularly in conditions like **shock**. - They cause **vasoconstriction (alpha-1 agonism)** and/or **increased cardiac output (beta-1 agonism)**, thereby raising blood pressure. - Agents like **norepinephrine, phenylephrine, and dopamine** are commonly used in critical care settings. *Acute decompensated heart failure* - Sympathomimetics with **beta-1 adrenergic agonist** effects (e.g., **dobutamine**) can improve cardiac contractility and output in acute decompensated heart failure. - These agents help to **increase myocardial performance** in situations where the heart is failing to pump adequately. - They provide temporary hemodynamic support in acute settings. *Nasal congestion* - **Alpha-1 adrenergic agonists** (e.g., **phenylephrine, pseudoephedrine**) are widely used as nasal decongestants. - They cause **vasoconstriction of nasal blood vessels**, reducing mucosal edema and improving airflow. - Available as both topical nasal sprays and oral formulations for symptomatic relief of nasal congestion.

Q: The neurotransmitters noradrenaline, adrenaline, and dopamine act through which of the following receptors?

Seven-pass transmembrane receptor. ***Seven-pass transmembrane receptor*** - Noradrenaline, adrenaline, and dopamine are **catecholamines** that primarily activate **G-protein coupled receptors (GPCRs)**, which are characterized by having seven transmembrane domains. - These receptors mediate a wide range of physiological responses by initiating **intracellular signaling cascades** upon ligand binding. *Single-pass transmembrane receptor* - These receptors, such as **receptor tyrosine kinases**, cross the membrane only once and typically dimerize upon ligand binding to activate their intracellular kinase domains. - While important for growth factors and hormones, they are **not the primary receptors** for catecholamines. *Four-pass transmembrane receptor* - This type of receptor structure is less common for neurotransmitters and is not characteristic of the established receptors for **noradrenaline, adrenaline, and dopamine**. - Examples include some **gap junction proteins** and a subset of ion channels, but not the **adrenergic** or **dopaminergic receptors**. *Ligand-gated ion channel* - These channels directly open in response to ligand binding, allowing ions to pass and rapidly changing the **membrane potential**. - While some neurotransmitters like **acetylcholine (nicotinic receptors)** and **GABA** act this way, catecholamines primarily exert their effects through **GPCRs**, which modulate ion channel activity indirectly.

Q: In thyrotoxicosis, which of the following symptoms is least effectively controlled by beta-blockers?

Oxygen consumption. ***Oxygen consumption*** - Beta-blockers primarily address the **adrenergic manifestations** of thyrotoxicosis, but they do not directly inhibit the increased **metabolic rate** or **thyroid hormone production** that drives higher oxygen consumption. - The elevated oxygen consumption in thyrotoxicosis is a direct result of enhanced cellular metabolism due to excess thyroid hormones, which beta-blockers do not counteract. *Tremors* - **Thyrotoxic tremors** are significantly mediated by **beta-adrenergic stimulation**, making them highly responsive to beta-blocker therapy. - Blocking beta-receptors reduces the sympathetic drive that contributes to these fine muscle tremors. *Tachycardia* - **Tachycardia** in thyrotoxicosis is a classic symptom of **increased sympathetic activity**, which beta-blockers effectively block. - Beta-blockers reduce heart rate by inhibiting beta-1 receptors in the myocardium, thereby relieving palpitations and rapid heart rate. *Anxiety* - **Anxiety** is often secondary to the **adrenergic overactivity** and overall heightened metabolic state associated with thyrotoxicosis. - By dampening the sympathetic nervous system, beta-blockers can alleviate anxiety and nervousness.

Q: What distinguishes betaxolol from timolol in terms of its pharmacological properties?

Is a selective β1 blocker. ***Is a selective β1 blocker*** - **Betaxolol** is a **cardioselective β1-adrenergic antagonist**, meaning it primarily blocks β1 receptors in the heart and **juxtaglomerular apparatus**. - **Timolol**, in contrast, is a **non-selective β-blocker**, affecting both β1 and β2 receptors, which can lead to more systemic side effects. *Has superior efficacy in treating glaucoma* - Both betaxolol and timolol are effective in **reducing intraocular pressure (IOP)** by decreasing aqueous humor production, with **timolol generally showing equivalent or slightly greater efficacy**. - **Timolol's non-selective action** may sometimes lead to a marginal advantage in IOP reduction, though **betaxolol is preferred** in some patients due to its selectivity. *Causes fewer ocular side effects than timolol* - While betaxolol is generally associated with **fewer systemic side effects** due to its cardioselectivity, it can actually cause **more ocular stinging and irritation** compared to timolol. - Some studies suggest a comparable incidence of other ocular side effects like **dry eye or blurred vision** between the two drugs. *Has a shorter duration of action than timolol* - Both betaxolol and timolol are applied **topically once or twice daily** to manage glaucoma, indicating a **similar long duration of action** suitable for sustained IOP control. - There is no clinical evidence to suggest that betaxolol has a significantly shorter duration of action that would warrant more frequent dosing compared to timolol.

Q: Which of the following drugs possesses the maximum action on nicotinic receptors?

Carbachol. ***Carbachol*** - **Carbachol** is a stable choline ester with prominent **nicotinic agonist activity**, making it the cholinergic agent with the greatest action on nicotinic receptors among the options listed. - Its **dual muscarinic and nicotinic effects** are due to its chemical structure, making it less selective than some other cholinergic agents. *Bethanechol* - **Bethanechol** is a choline ester that primarily acts on **muscarinic receptors** and has very little to no nicotinic activity. - It is used clinically for its muscarinic effects, such as increasing **bladder motility** or treating **gastric atony**. *Pilocarpine* - **Pilocarpine** is an alkaloid with strong, selective **muscarinic agonist activity**, making it particularly useful for conditions like **glaucoma** (by increasing aqueous humor outflow) and **xerostomia**. - It exhibits negligible activity at **nicotinic receptors**. *Methacholine* - **Methacholine** is a choline ester that primarily stimulates **muscarinic receptors**, though it has more nicotinic action than bethanechol. - It is known for its use in **bronchial challenge tests** to diagnose **asthma** due to its role in causing bronchoconstriction via muscarinic stimulation.

Q: Which short-acting anticholinesterase drug is primarily used for the diagnosis of myasthenia gravis?

Edrophonium. ***Edrophonium*** - This **short-acting anticholinesterase** reversibly inhibits acetylcholinesterase, leading to a temporary increase in acetylcholine at the neuromuscular junction. - The **Tensilon test** uses edrophonium to rapidly assess for improved muscle strength in patients suspected of having myasthenia gravis. *Demecarium* - This is a **long-acting cholinesterase inhibitor** and is not typically used for the fast diagnostic test of myasthenia gravis due to its extended duration of action. - It was historically used in the treatment of glaucoma, not for acute diagnostic purposes in neuromuscular disorders. *Dyflos* - Also known as **diisopropyl fluorophosphate (DFP)**, Dyflos is an **irreversible organophosphorus cholinesterase inhibitor**. - Its long-lasting and toxic effects make it unsuitable and dangerous for diagnostic testing of myasthenia gravis. *Echothiophate* - This is another **long-acting, irreversible cholinesterase inhibitor** primarily used in the treatment of glaucoma. - Its irreversible nature and prolonged effects are not suitable for the quick, reversible diagnostic test needed for myasthenia gravis.

Question 1

Cholinomimetic is not used for:

Accepted Answer

Bradycardia

Answer

Cobra bite

Answer

Myasthenia gravis

Answer

Open angle glaucoma

Question 2

Which of the following drugs is not used for the treatment of overactive bladder?

Accepted Answer

Duloxetine

Answer

Oxybutynin

Answer

Flavoxate

Answer

Darifenacin

Question 3

The H3 receptor agonist exhibits all of the following actions except:

Accepted Answer

Increase in H2 mediated gastric secretion

Answer

Inhibition of H1 mediated bronchoconstriction

Answer

Negative chronotropic effect on atria

Answer

Inhibition of H1 receptors induced wakefulness

Question 4

Which of the following is not a carbamate?

Accepted Answer

Edrophonium

Answer

Physostigmine

Answer

Neostigmine

Answer

Pyridostigmine

Question 5

Sympathomimetic drugs are useful in the therapy of all of the following conditions except:

Accepted Answer

Hypertension

Answer

Hypotension

Answer

Acute decompensated heart failure

Answer

Nasal congestion

Question 6

The neurotransmitters noradrenaline, adrenaline, and dopamine act through which of the following receptors?

Accepted Answer

Seven-pass transmembrane receptor

Answer

Single-pass transmembrane receptor

Answer

Four-pass transmembrane receptor

Answer

Ligand-gated ion channel

Question 7

In thyrotoxicosis, which of the following symptoms is least effectively controlled by beta-blockers?

Accepted Answer

Oxygen consumption

Answer

Tremors

Answer

Tachycardia

Answer

Anxiety

Question 8

What distinguishes betaxolol from timolol in terms of its pharmacological properties?

Accepted Answer

Is a selective β1 blocker

Answer

Has superior efficacy in treating glaucoma

Answer

Causes fewer ocular side effects than timolol

Answer

Has a shorter duration of action than timolol

Question 9

Which of the following drugs possesses the maximum action on nicotinic receptors?

Accepted Answer

Carbachol

Answer

Bethanechol

Answer

Pilocarpine

Answer

Methacholine

Question 10

Which short-acting anticholinesterase drug is primarily used for the diagnosis of myasthenia gravis?

Accepted Answer

Edrophonium

Answer

Demecarium

Answer

Dyflos

Answer

Echothiophate

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?